Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.80 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.80 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.80 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.33 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13589890 | 0.89 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7ALDH1A1CHRNA3 | |
| SCHEMBL160708 | 0.89 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7ALDH1A1CHRNA3 | |
| SCHEMBL21307962 | 0.89 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7ALDH1A1CHRNA3 | |
| Trifluoroacetic Acid SCHEMBL16431875 | 0.85 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNA7ALDH1A1CHRNA3 | |
| SCHEMBL21308152 | 0.73 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNA7ALDH1A1CHRNA3 | |
| SCHEMBL12102742 | 0.73 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNA7ALDH1A1CHRNA3 | |
| Trifluoroacetic Acid SCHEMBL3902122 | 0.69 | ALDH1A1 (0.38) | CHRNB2CHRNA4CHRNA7ALDH1A1CHRNA3 | |
| SCHEMBL23613217 | 0.65 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNA7ALDH1A1CHRNA3 | |
| Trifluoroacetic Acid SCHEMBL21598176 | 0.64 | KDM1A (0.33) | CHRNB2CHRNA4CHRNA7CHRNA3 | |
| Trifluoroacetic Acid SCHEMBL939167 | 0.63 | ARG1 (0.34) | CHRNB2CHRNA4CHRNA7CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114544835-B | Preparation and quantitative analysis method of high-purity cyanobacteria polypeptide metabolite | 舟山市食品药品检验检测研究院 | 2024-07-09 | — | — | CN | claimed |
| CN-114544835-A | Preparation and quantitative analysis method of high-purity blue algae polypeptide metabolite | 舟山市食品药品检验检测研究院 | 2022-05-27 | — | — | CN | claimed |
| US-7428045-B2 | Raman spectral analysis of pathogens | CHEMIMAGE CORPORATION (US) | 2008-09-23 | — | — | US | claimed |
| EP-1915597-A2 | RAMAN SPECTRAL ANALYSIS OF PATHOGENS | Chemimage Corporation (US) | 2008-04-30 | — | — | EP | claimed |
| WO-2007021485-A2 | RAMAN SPECTRAL ANALYSIS OF PATHOGENS | CHEMIMAGE CORPORATION (US) | 2007-02-22 | — | — | WO | claimed |
| US-20060055923-A1 | Raman spectral analysis of pathogens | CHEMIMAGE CORPORATION | 2006-03-16 | — | — | US | claimed |
| CN-114544835-B | Preparation and quantitative analysis method of high-purity cyanobacteria polypeptide metabolite | 舟山市食品药品检验检测研究院 | 2024-07-09 | — | — | CN | disclosed |
| EP-4051247-B1 | TRANSDERMAL PATCH | UNIV OF SUNDERLAND (GB) | 2023-11-01 | — | — | EP | disclosed |
| US-20230173090-A1 | COMPOSITIONS AND METHODS FOR MODULATING DOPAMINE RECEPTOR ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-08 | — | — | US | disclosed |
| WO-2023097186-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VISUAL FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-01 | — | — | WO | disclosed |
| EP-4172187-A1 | COMPOSITIONS AND METHODS FOR MODULATING DOPAMINE RECEPTOR ACTIVITY | The Regents of the University of California (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-4158002-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VISUAL FUNCTION | The Regents of the University of California (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220387342-A1 | TRANSDERMAL PATCH | UNIVERSITY OF SUNDERLAND (GB) | 2022-12-08 | — | — | US | disclosed |
| WO-1999051764-A1 | METHOD FOR DETECTION OF BACILLUS CEREUS EMETIC TOXIN AND A KIT THEREFOR | LOCUS GENEX OY (FI) | 1999-10-14 | — | — | WO | disclosed |
| EP-0760681-B1 | MODIFICATION OF CLOSTRIDIAL TOXINS FOR USE AS TRANSPORT PROTEINS | ALLERGAN INC (US) | 1999-09-01 | — | — | EP | disclosed |
| US-5821249-A | Anhydroecogonine compounds and their use as anticholinergic agents | UNIVERSITY OF ROCHESTER (US) | 1998-10-13 | — | — | US | disclosed |
| EP-0760681-A1 | MODIFICATION OF CLOSTRIDIAL TOXINS FOR USE AS TRANSPORT PROTEINS | ALLERGAN, INC (US) | 1997-03-12 | — | — | EP | disclosed |
| US-5552407-A | Anhydroecgonine compounds and their use as anticholinergic agents | NEW YORK UNIVERSITY MEDICAL CENTER (US) | 1996-09-03 | — | — | US | disclosed |
| WO-1995032738-A1 | MODIFICATION OF CLOSTRIDIAL TOXINS FOR USE AS TRANSPORT PROTEINS | ALLERGAN, INC. (US) | 1995-12-07 | — | — | WO | disclosed |
| WO-1994029306-A1 | COCAINE DERIVATIVES AND THEIR USE AS ANTICHOLINERGIC AGENTS | NEW YORK UNIVERSITY (US) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173090-A1 | COMPOSITIONS AND METHODS FOR MODULATING DOPAMINE RECEPTOR ACTIVITY | PARK7, PRLHR, SNCA | CHRNB2 4/4885CHRNA4 31/4885CHRNA7 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.